Lymphoblastoid human interferon and low dose IL-2 combined with donor lymphocyte infusion as therapy of a third relapse of CML - A case report

Bone Marrow Transplantation

Volumn 18, Issue 1, 1996, Pages 241-242

  Lonnqvist B ^a   Brune, M ^b   Ljungman, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BMT; CML relapse; Donor lymphocyte; Human IFN; IL 2

Indexed keywords

ALPHA INTERFERON; HUMAN INTERFERON; INTERLEUKIN 2;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; GENE TRANSLOCATION; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOCYTE TRANSFUSION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; REMISSION;

ADULT; BIOLOGICAL RESPONSE MODIFIERS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DISEASES IN TWINS; HUMANS; INTERFERON ALFA-2A; INTERLEUKIN-2; LEUKEMIA, MYELOID, CHRONIC-PHASE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LYMPHOCYTE TRANSFUSION; MALE; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029782076     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Aschan J, Ringdén O, Sundberg B et al. Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host disease. Eur J Haematol 1993: 50: 269-274.
2. Kolb HJ, Mittermüller J, Clemm Ch et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
3. Hauch M, Gazzola MV, Small T et al. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990; 75: 2250-2262.
4. Slavin S, Weiss S, Ackerstein A et al. Prevention and treatment of relapse by bone marrow transplantation. Bone Marrow Transplant 1993; 12 (Suppl. 3): 54-56.
5. Lee MS, Chang KS, Freirich EJ et al. Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction. Blood 1988; 72: 893-897.
6. Kolb HJ, Schattenberg A, Goldman J et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
7. Porter DL, Roth MS, McCarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994; 330: 100-106.
8. Caron PC, Scheinberg DA. Immunotherapy for acute leukemias. Curr Opin Oncol 1994; 6: 14-22.
9. Brune M, Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukemia. Br J Haematol 1996; 92: 620-626.
10. Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991; 77: 874-878.